DNA research concept DNA barcodes for biomedical research  mitochondrial DNA  Prostate cancer DNA test

8 Companion Diagnostic Developers Making a Mark

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Projections for the growth of the liquid biopsy market range as low as $1 billion by 2020

10 Liquid Biopsy Companies in the Money

10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
Depressed woman with head in hands

UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...

PerkinElmer Genomics, U. of Iowa Develop FSHD Assay Based on Bionano’s Saphyr

Bionano Genomics announced at the American Society of Human Genetics (ASHG) annual meeting in Houston that PerkinElmer Genomics and the University of Iowa have...

Small Sequencer Developer GenapSys Completes $90M Series C Financing

GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Scientist holding a DNA sample with the results on a computer sceeen in a laboratory

Invitae Offers Free Genetic Testing for Four Conditions

Invitae said it is offering for free its Detect genetic testing programs for four conditions: Muscular dystrophy, hereditary prostate cancer, familial cardiomyopathy and arrhythmia,...
The American Association of Clinical Urologists (AACU) has issued a position statement encouraging the use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients. [Ji-Xin Cheng

Clinical Urologists Group Supports Genomic Testing for Prostate Cancer

AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients

10x Genomics Graduates from ‘Super Success’ to $100M IPO

10x Genomics has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities...
digital dna

Artificial Intelligence Enhances Oncology

The volume of information that needs to be analyzed to make precision medicine a reality in cancer care is often beyond the realm of the human mind. That’s where artificial intelligence steps in

Five-Year Super Successes in Genomics and Precision Medicine

Multidimensional, computationally rich approaches represent the next wave of innovation, taking personalized medicine to the next level, while demanding more of practitioners, who in...
Scroll Up